12
Participants
Start Date
November 30, 2009
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
Surgery
surgical resection to remove all known disease
Surgery plus 2 adjuvant doses of BCG
Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
best medical therapy
Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
Princess Alexandra Hospital, Brisbane
Buffalo General Hospital, Buffalo
Penn State Hershey Cancer Center, Hershey
Geisinger Clinic, Wilkes-Barre
Main Line Health System, Wynnewood
Thomas Jefferson University, Philadelphia
Wake Forest University, Winston-Salem
Ohio State University Medical Center, Columbus
Mayo Clinic Cancer Center, Rochester
Rush University, Chicago
Dallas Surgical Group, Dallas
Istituto Nazionale dei Tumori Napoli, Naples
Huntsman Cancer Institute, Salt Lake City
IHC Cancer Services Intermountain Healthcare, Murray
John Wayne Cancer Institute, Santa Monica
Tel-Aviv Sourasky Medical Center, Tel Aviv
UC Davis Medical Center, Sacramento
UT Southwestern Medical Center at Dallas, Dallas
Univesitair Medisch Centrum Groningen, Groningen
Collaborators (1)
Melanoma Research Alliance
OTHER
Saint John's Cancer Institute
OTHER